{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tretinoin&page=2", "query": { "intervention": "tretinoin", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 185, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tretinoin&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tretinoin&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T19:49:49.563Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003405", "title": "Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "bromodeoxyuridine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "idarubicin", "type": "DRUG" }, { "name": "idoxuridine", "type": "DRUG" }, { "name": "isotretinoin", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "0 Years to 70 Years" }, "enrollment_count": 0, "start_date": "1998-04", "completion_date": "1999-04", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-10-02T19:49:49.563Z", "location_count": 4, "location_summary": "Chicago, Illinois • Kankakee, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kankakee", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003405" }, { "nct_id": "NCT01175356", "title": "Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ganglioneuroblastoma", "Localized Resectable Neuroblastoma", "Localized Unresectable Neuroblastoma", "Regional Neuroblastoma", "Stage 4 Neuroblastoma", "Stage 4S Neuroblastoma" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "In Vitro-Treated Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Iobenguane I-131", "type": "RADIATION" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 99, "start_date": "2011-12-21", "completion_date": "2025-12-31", "has_results": true, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-10-02T19:49:49.563Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01175356" }, { "nct_id": "NCT01125930", "title": "Atralin Gel for the Treatment of Rosacea", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rosacea" ], "interventions": [ { "name": "vehicle gel", "type": "DRUG" }, { "name": "Atralin gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lisa E. Maier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2010-05", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2014-07-16", "last_synced_at": "2026-10-02T19:49:49.563Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01125930" }, { "nct_id": "NCT02279095", "title": "An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fibrodysplasia Ossificans Progressiva" ], "interventions": [ { "name": "Palovarotene dose level 1", "type": "DRUG" }, { "name": "Palovarotene dose level 2", "type": "DRUG" }, { "name": "Palovarotene dose level 3", "type": "DRUG" }, { "name": "Palovarotene dose level 4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clementia Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "6 Years to 65 Years" }, "enrollment_count": 58, "start_date": "2014-10-09", "completion_date": "2022-09-20", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-10-02T19:49:49.563Z", "location_count": 3, "location_summary": "San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02279095" }, { "nct_id": "NCT00324740", "title": "Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Renal Cell Cancer", "Stage III Renal Cell Cancer", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "vorinostat", "type": "DRUG" }, { "name": "isotretinoin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 14, "start_date": "2006-03", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2021-02-23", "last_synced_at": "2026-10-02T19:49:49.563Z", "location_count": 2, "location_summary": "New York, New York • The Bronx, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324740" }, { "nct_id": "NCT01820624", "title": "Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "tretinoin", "type": "DRUG" }, { "name": "lithium carbonate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Paolo Caimi, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2013-04-30", "completion_date": "2015-11-13", "has_results": false, "last_update_posted_date": "2017-04-27", "last_synced_at": "2026-10-02T19:49:49.563Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01820624" }, { "nct_id": "NCT00167219", "title": "Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Juvenile Myelomonocytic Leukemia" ], "interventions": [ { "name": "Stem Cell Transplant", "type": "BIOLOGICAL" }, { "name": "Preparative Regimen", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 15, "start_date": "1999-11-18", "completion_date": "2023-08-09", "has_results": true, "last_update_posted_date": "2023-11-07", "last_synced_at": "2026-10-02T19:49:49.563Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00167219" }, { "nct_id": "NCT05999812", "title": "Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "all trans Retinoic Acid", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2023-12-19", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-02T19:49:49.563Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05999812" }, { "nct_id": "NCT01183884", "title": "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Months", "maximum_age": null, "sex": "ALL", "summary": "18 Months and older" }, "enrollment_count": 46, "start_date": "2010-08", "completion_date": "2018-11-09", "has_results": true, "last_update_posted_date": "2019-11-14", "last_synced_at": "2026-10-02T19:49:49.563Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183884" }, { "nct_id": "NCT01985477", "title": "Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "All-Trans Retinoic Acid (ATRA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2013-12", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2016-09-14", "last_synced_at": "2026-10-02T19:49:49.563Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01985477" } ] }